Document is current

Article History

Received: 25 June 2023

Revised: 23 October 2023

Accepted: 31 October 2023

First Online: 28 November 2023

Declarations

:

: Kensuke Usuki has received research funding from Astellas, AbbVie, Bristol-Myers Squibb, Janssen, Ono, Otsuka, Chugai, Aperis, Yakult, MSD, Amgen, Alxion, Incyte, Eisai, Kyowa-Kirin, Sanofi, SymBio, Celgene, Daichi Sankyo, Sumitomo-Dainippon, Nippon Shinyaku, Novartis, Mundi, and Takeda, has served on speaker bureaus for Novartis, Abbvie, Alexion, Incyte, Ono, Kyowa-Kirin, Sanofi, Takeda, Nippon-Shinyaku, Pfizer, and Bristol-Myers Squibb, and has served on consulting bureaus for Astellas, Amgen, Alnylam Japan, Alexion, Eisai, Otsuka, Ohara, Kyowa-Kirin, Sanofi, Sando, SymBio, Takeda, Chugai, and Nippon Shinyaku; Hisayuki Yokoyama has served on speaker bureaus for Astellas Pharma; Hiroshi Handa received research funding from Kyowa-Kirin Pharmaceutical, Chugai Pharmaceutical, and Dai-ich Sankyo; Shuichi Ota1 has served on speaker bureaus for Novartis, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, AstraZeneca, Janssen Pharmaceutical K.K., and Abbvie; Katsumichi Fujimaki has served on speaker bureaus for Otsuka Pharmaceuticals; Kensuke Kojima has served on speaker bureaus for Janssen, AstraZeneca, and Abbvie; Tomohiro Kajiguchi has served on speaker bureaus for Janssen Pharmaceutical, Novartis, Otsuka Pharmaceutical, Ono Pharmaceutical, Nippon Shinyaku, Sanofi, Abbvie, Pfizer, Bristol-Myers Squibb, Kyowa-Kirin, Chugai Pharmaceutical, AstraZeneca, Takede Pharmaceuticals, and Mundipharma; Norio Asou received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, and Eisai and has served on Advisory Board for Nippon Shinyaku, and Novartis Pharma; Noriko Usui has served on speaker bureaus for Nippon Shinyaku, AbbVie, and Daiichi Sankyo, and has served on consulting bureaus for CMIC Co., Ltd.; Itaru Matsumura received research funding from Ono Pharmaceutical, Janssen Pharmaceutical, Nippon Shinyaku, Kyowa-Kirin, Sumitomo Dainippon Pharma, Shionogi, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical, Eisai, MSD, Asahi Kasei Pharma, Astellas Pharma, Takeda Pharmaceutical, Nihon Pharmaceutical, Daiichi Sankyo, AbbVie, Taiho Pharaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, CSL Behring, Mundipharma, Ayumi Pharmaceutical, Eli Lilly Japan, Actelion Pharmaceuticals Japan, and Amgen BioPharma, has served on speaker bureaus for Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, Otsuka Pharmaceutical, Pfizer Japan, Janssen Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, SymBio Pharmaceuticals, AbbVie, Amgen BioPharma, and has served on consulting bureaus for Otsuka Pharmaceutical; Yasushi Miyazaki has served on speaker bureaus for ovartis, Abbvie, Nppon-Shinyaku, Astellas, Sumitomo Pharma, and Synbio; Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Satoru Takada, Daiki Hirano, Tatsuki Tomikawa, Masahiko Sumi, Shingo Yano, Hiroyuki Fujita, Atsuko Mugitani, Ko Fujimoto, Yuichi Ishikawa, Akira Katsumi, Hitoshi Kiyoi have nothing to disclose.